Terbinafine in the treatment of cutaneous leishmaniasis: A pilot study

International Journal of Dermatology

Volumn 36, Issue 1, 1997, Pages 59-60

  Bahamdan, Khalid A ^b   Tallab, Talal M ^a   Johargi, Hanan ^b   Nourad, Mohamed Mazen ^b   Ibrahim, Karam ^b   El Sherbini, Abdulk Hameed ^b   Karkashan, Eman ^b   Khare, Ashok K ^b   Nauri, Mustafa M ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

STIBOGLUCONATE SODIUM; TERBINAFINE;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INTRADERMAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS;

EID: 0030993548     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1997.00021.x     Document Type: Article

References (17)

1. Urcuyo FC, Zaias N. Oral ketoconazole in the treatment of cutaneous leishmaniasis. Int J Dermatol 1982; 21: 414-415.
2. Weinrauch L, Livshin R, El-On J. Efficacy of ketoconazole in cutaneous leishmaniasis. Arch Dermatol Res 1983; 275: 353-354.
3. Alsaleh Q, Dvorak R, Nanda A. Ketoconazole in the treatment of cutaneous leishmaniasis. Int J Dermatol 1995; 34: 495-497.
4. Alfouzan A, Asaleh Q, Najem N, et al. Cutaneous leishmaniasis in Kuwait: clinical experience with itraconazole. Int J Dermatol 1991; 30: 519-521.
5. Dogra J, Anega N, Lal B, et al. Cutaneous leishmaniasis in India: clinical experience with itraconazole (R51 211 Janssen). Int J Dermatol 1990; 29: 661-662.
6. Enden EV, Gomple A, Stevens A, et al. Treatment of cutaneous leishmaniasis with oral itraconazole. Int J Dermatol 1994; 33: 285-286.
7. Beach DH, Holtz GG, Anchlwe GE. Lipid of leishmania promastigotes. J Parasitol 1979; 65: 203-216.
8. Ryder NS, Mieth H. Allylamine antifungal drugs. Curr Trop Med Mycol 1992; 47: 158-188.
9. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibitor. Br J Dermatol 1992; 126 (Suppl. 39): 27.
10. Ottervanger JP, Stroker BH. Loss of taste and Terbinafine. Lancet 1992; 340 (8821): 728.
11. Lowe G, Geen C, Jennings P. Hepatitis associated with terbinafine treatment. BMJ 1993; 306 (6872): 248.
12. McGregor JM, Rustin MH. Terbinafine and erythema multiforme. Br J Dermatol 1994; 131: 587-588.
13. Carstens J, Wendelboe P, Sogaard H, et al. Toxic epidermal necrolysis follow therapy with terbinafine. Acta Derm Venereol (Stockh) 1994; 74: 391-392.
14. Kovacs MJ, Al-shammari S, Guenthor L, et al. Neurotropenia and pancytopenia associated with terbinafine. J Am AcadDermatol 1994; 31: 806.
15. Goad LJ, Hole GG, Reach DH. Effect of allylamine antifungal drug SF86-327 on the growth and sterol synthesis of leishmania mexicana promastigtes. Biochem Pharmacol 1985; 34: 3785-3788.
16. Maldonado RA, Molina J, Payares G, et al. Experimental chemotherapy with combination of ergosterol biosynthesis inhibitors in murine models of Chaga's disease. Antimicrob Agents Chemother 1993; 37: 1353-1359.
17. Al-zahrani MA, Peters W, Evans A, et al. Leishmania infecting man and wild animals in Saudi Arabia. 6. Cutaneous leishmaniasis of man in the south-west. Trans Soc Trop Med Hyg 1989; 83: 621-628.